{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:50:33Z","timestamp":1792529433492,"version":"4.5.0"},"reference-count":55,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["C11711734926"],"award-info":[{"award-number":["C11711734926"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: To date, there are no studies associating the dried blood spot (DBS) levels of globotrioasylsphingosine (lysoGb3) with quantitative optical coherence tomography angiography (OCTA) parameters in Fabry disease (FD) patients. Here, we aimed to investigate the association between OCTA vessel density (VD), vessel length density (VLD) with DBS lysoGb3. Methods: A retrospective, single center analysis of all consecutive FD patients enrolled at the Department of Ophthalmology of the University Hospital of Zurich from 1 December 2017 to 9 September 2020. An association between VD and VLD detected by OCTA and lysoGb3 was investigated using a linear mixed model. Results: A total of 57 FD patients (23 male, 34 female; 109 eyes) were included. Forty-one patients suffered from the classic phenotype and 16 from the later-onset phenotype. LysoGb3 inversely correlated with VD and VLD in both the superficial (VD: p = 0.034; VLD: p = 0.02) and deep capillary plexus (VD: p = 0.017; VLD: p = 0.018) in the overall FD cohort. Conclusions: Our study shows an association between lysoGb3 and OCTA VD and VLD. This supports the hypothesis that quantitative OCTA parameters might be useful as diagnostic biomarkers for evaluating systemic involvement in FD, and possibly other diseases.<\/jats:p>","DOI":"10.3390\/jcm10051093","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T11:46:09Z","timestamp":1614944769000},"page":"1093","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Globotrioasylsphingosine Levels and Optical Coherence Tomography Angiography in Fabry Disease Patients"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-1805","authenticated-orcid":false,"given":"Maximilian Robert Justus","family":"Wiest","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-2613","authenticated-orcid":false,"given":"Mario Damiano","family":"Toro","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medical Sciences, Collegium Medicum, Cardinal Stefan Wyszy\u0144ski University, 01815 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-5516","authenticated-orcid":false,"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Clinical Nutrition, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"},{"name":"Department of Internal Medicine, Psychiatry University Clinic Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Baur","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-961X","authenticated-orcid":false,"given":"Katrin","family":"Fasler","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hamann","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayss","family":"Al-Sheikh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Anne","family":"Zweifel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","first-page":"e113","article-title":"Computer assisted evaluation of retinal vessels tortuosity in Fabry disease","volume":"91","author":"Sodi","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"ref_2","unstructured":"Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. (2001). \u03b1-galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease, The McGraw-Hill Companies Inc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/0929867324666170616102112","article-title":"Biomarkers for Diagnosing and Staging of Fabry Disease","volume":"25","author":"Kramer","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/00141844.2015.1110190","article-title":"Computer Assisted Retinal Vessel Tortuosity Evaluation in Novel Mutation Fabry Disease: Towards New Prognostic Markers","volume":"37","author":"Rodriguez","year":"2017","journal-title":"Retina"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2017.09.027","article-title":"Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up","volume":"249","author":"Siegenthaler","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_6","first-page":"174","article-title":"Fabry Disease (\u03b1-Galactosidase A Deficiency): Renal Involvement and Enzyme Replacement Therapy","volume":"136","author":"Desnick","year":"2001","journal-title":"Proteom. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of Lysosomal Storage Disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_9","unstructured":"Beaudet, A.L., Vogelstein, B., and Kinzler, K.W. (2014). \u03b1-Galactosidase A Deficiency: Fabry Disease. The Online Metabolic and Molecular Bases of Inherited Disease, The McGraw-Hill Companies Inc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med Genet."},{"key":"ref_12","first-page":"313","article-title":"Corneal Ultrastructural Changes in Fabry\u2019s Disease","volume":"176","author":"Francois","year":"1978","journal-title":"Int. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1755-3768.1981.tb08733.x","article-title":"Fabry\u2019s disease and cornea verticillata. A report of 3 cases","volume":"59","author":"Tuppurainen","year":"1981","journal-title":"Acta Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/13816818509006132","article-title":"Corneal changes in Fabry\u2019s disease: A clinico-pathologic case report of a heterozygote","volume":"5","author":"Macrae","year":"1985","journal-title":"Ophthalmic Paediatr. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2006.100602","article-title":"Ocular manifestations of Fabry\u2019s disease: Data from the Fabry Outcome Survey","volume":"91","author":"Sodi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.survophthal.2008.04.005","article-title":"Ocular Features of Fabry Disease: Diagnosis of a Treatable Life-threatening Disorder","volume":"53","author":"Samiy","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: Lessons from two \u03b1-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme Replacement Therapy for Lysosomal Diseases: Lessons from 20 Years of Experience and Remaining Challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","first-page":"100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"Spaide","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamaophthalmol.2014.3616","article-title":"Retinal Vascular Layers Imaged by Fluorescein Angiography and Optical Coherence Tomography Angiography","volume":"133","author":"Spaide","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_25","first-page":"e563","article-title":"Vascular changes after vitrectomy for rhegmatogenous retinal detachment: Optical coherence tomography angiography study","volume":"98","author":"Bonfiglio","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_26","first-page":"1","article-title":"Secondary Vitrectomy with Internal Limiting Membrane Plug due to Persistent Full-Thickness Macular Hole OCT-Angiography and Microperimetry Features: Case Series","volume":"2020","author":"Nowomiejska","year":"2020","journal-title":"J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Carnevali, A., Mastropasqua, R., Gatti, V., Vaccaro, S., Mancini, A., D\u2019Aloisio, R., Lupidi, M., Cerquaglia, A., Sacconi, R., and Borrelli, E. (2020). Optical Coherence Tomography Angiography in Intermediate and Late Age-Related Macular Degeneration: Review of Current Technical Aspects and Applications. Appl. Sci., 10.","DOI":"10.3390\/app10248865"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cennamo, G., Di Maio, L.G., Montorio, D., Tranfa, F., Russo, C., Pontillo, G., Cocozza, S., Esposito, R., Di Risi, T., and Imbriaco, M. (2019). Optical Coherence Tomography Angiography Findings in Fabry Disease. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040528"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1167\/iovs.18-26052","article-title":"Macular Impairment in Fabry Disease: A Morpho-functional Assessment by Swept-Source OCT Angiography and Focal Electroretinography","volume":"60","author":"Minnella","year":"2019","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s10792-020-01486-2","article-title":"Optical coherence tomography angiography analysis of fabry disease","volume":"40","author":"Cakmak","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cennamo, G., Montorio, D., Santoro, C., Cocozza, S., Spinelli, L., Di Risi, T., Riccio, E., Russo, C., Pontillo, G., and Esposito, R. (2020). The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9124087"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1120672119880390","article-title":"Optical coherence tomography angiography and arterial hypertension: A role in identifying subclinical microvascular damage?","volume":"31","author":"Donati","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography\u2013Tandem Mass Spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"(1991). Early Treatment Diabetic Retinopathy Study Design and Baseline Patient Characteristics; ETDRS report number 7. Ophthalmology, 98, 741\u2013756.","DOI":"10.1016\/S0161-6420(13)38009-9"},{"key":"ref_36","first-page":"1","article-title":"Impact of image quality on OCT angiography based quantitative measurements","volume":"3","author":"Falavarjani","year":"2017","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00592-017-0996-8","article-title":"Optical coherence tomography angiography analysis of retinal vascular plexuses and choriocapillaris in patients with type 1 diabetes without diabetic retinopathy","volume":"54","author":"Carnevali","year":"2017","journal-title":"Acta Diabetol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/bjophthalmol-2016-309481","article-title":"Choroid morphometric analysis in non-neovascular age-related macular degeneration by means of optical coherence tomography angiography","volume":"101","author":"Cicinelli","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ehf2.12647","article-title":"Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: A pre-treatment vs. post-treatment analysis","volume":"7","author":"Wanner","year":"2020","journal-title":"ESC Hear. Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e000277","DOI":"10.1136\/bmjresp-2018-000277","article-title":"Pulmonary involvement in Fabry disease: Effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy","volume":"5","author":"Franzen","year":"2018","journal-title":"BMJ Open Respir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: Natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3892\/ijmm_00000246","article-title":"Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model","volume":"24","author":"Jung","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10545-009-1060-9","article-title":"Leukocyte perturbation associated with Fabry disease","volume":"32","author":"Rozenfeld","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.mrgentox.2015.04.012","article-title":"DNA damage in Fabry patients: An investigation of oxidative damage and repair","volume":"784\u2013785","author":"Biancini","year":"2015","journal-title":"Mutat. Res. Toxicol. Environ. Mutagen."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol. Biosyst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/jhg.2015.123","article-title":"Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease","volume":"61","author":"Ko","year":"2015","journal-title":"J. Hum. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: A key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Cordon, B., Vilades, E., Orduna, E., Satue, M., Perez-Velilla, J., Sebastian, B., Polo, V., Larrosa, J.M., Pablo, L.E., and Garcia-Martin, E. (2020). Angiography with optical coherence tomography as a biomarker in multiple sclerosis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243236"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pellegrini, M., Vagge, A., Desideri, L.F.F., Bernabei, F., Triolo, G., Mastropasqua, R., Del Del Noce, C., Borrelli, E., Sacconi, R., and Iovino, C. (2020). Optical Coherence Tomography Angiography in Neurodegenerative Disorders. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061706"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lin, Z., Pan, X., Mao, K., Jiao, Q., Chen, Y., Zhong, Y., and Cheng, Y. (2021). Quantitative evaluation of retinal and choroidal changes in Fabry disease using optical coherence tomography angiography. Lasers Med. Sci., 1\u20139.","DOI":"10.1007\/s10103-020-03242-5"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/5\/1093\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:43Z","timestamp":1760160823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/5\/1093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["jcm10051093"],"URL":"https:\/\/doi.org\/10.3390\/jcm10051093","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}